Compare Johnson & Johnson (JNJ) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs IAC/Interactivecorp — how do they compare? Johnson & Johnson trades at $260.45 (market cap $618.09B), while IAC/Interactivecorp trades at $41.23 (market cap $3.05B). The key difference: Johnson & Johnson is far larger — about 202.7× IAC/Interactivecorp's market cap, and Johnson & Johnson pays a 2.09% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and IAC/Interactivecorp for 79 Days on average.
| JNJ | PPLI | |
|---|---|---|
Market Cap | $618.09B | $3.05B |
Volume | 6,050,983 | 931,019 |
Sector | Health | Media |
52-Week High | $278.43 | $47.62 |
52-Week Low | $186.00 | $31.52 |
Typical Hold Time | 129 Days | 79 Days |
Enterprise Value | $646.37B | $3.53B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
PPLI trades at $40.85, up 0.64% on the day, with a bullish technical signal from moving averages. The stock has shown volatile earnings, missing estimates in Q4 2025 and Q1 2026 but beating in Q2 2026. Recent news highlights potential M&A activity, with MGM Resorts considering a bid for the company after PPLI withdrew its own offer to buy MGM, driving significant price movement. Valuation ratios appear attractive with a P/E of 6.92 and P/B of 0.6, though profitability metrics are mixed amid revenue declines from $5.2B in 2022 to $2.4B in 2025.
The outlook is cautiously optimistic due to strong analyst support (71.43% buy ratings) and speculative M&A upside, but risks include inconsistent earnings, high debt levels, and competitive pressures in the media sector. Net cash flow turned deeply negative in 2025 at -$820.42M, underscoring financial volatility. Investors should weigh the low valuation against execution challenges and industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
